P53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes

  • Amrein L
  • Soulières D
  • Johnston J
 et al. 
  • 31


    Mendeley users who have this article in their library.
  • 23


    Citations of this article.


B-cell chronic lymphocytic leukemia (CLL) is the most common leukemia in adults and there is no cure for the disease. Although dasatinib is cytotoxic to primary CLL lymphocytes in vitro, the drug has been shown to be active in a small percent of CLL patients. Our previous results suggest that dasatinib targets del17 CLL lymphocytes which are the CLL patients with the worst prognosis. Here we present mechanistic evidence that dasatinib induces endoplasmic reticulum stress and autophagy in CLL lymphocytes. Furthermore we provide evidence suggesting that autophagy mediates resistance to the drugs, process that is modulated by p53. © 2010 Elsevier Ltd.

Author-supplied keywords

  • Autophagy
  • CLL
  • Dasatinib
  • P53

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free